Mesoblast completes Phase 3 low back pain trial treatment as pivotal readout approaches
Mesoblast has completed treatment of 350 patients in its pivotal Phase 3 trial for chronic low back pain, with results expected in mid-2027.
Market Cap $6.242M
!
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Strike Resources Limited
| Forum | Tag | Subject | View | Poster | |||||
|---|---|---|---|---|---|---|---|---|---|
| ASX - By Stock | SRK | Ann: Half Year Report - 31 December 2017 | Thread |
ASX News
|
0 | 162 | 0 | 13/03/18 | |
|
|||||||||
| ASX - By Stock | SRK | Re: Ann: Peru Update - MOU with Dalian Huarui Heavy Industry Group | Thread | huninni | 2 | 794 | 1 | 26/02/18 | |
|
|||||||||
ASX News